StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$23.10−0.20 (-0.86%)

Close on Nov 17, 2026Market cap $462.26MP/E –Yield –

Neurogene cash

Cash and short-term investments held at the end of each period.

Neurogene's cash was $225.39M at Jun 30, 2026. For fiscal 2025 it was $269.00M, down 13.9% from the year before. Over ten years it grew 21.1% a year on average. The highest annual figure on record is $312.40M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$269.00M-13.9%
FY2024Dec 31, 2024$312.40M+58.0%
FY2023Dec 31, 2023$197.67M+141.0%
FY2022Dec 31, 2022$82.02M+16.3%
FY2021Dec 31, 2021$70.54M-63.5%
FY2020Dec 31, 2020$193.43M+35.2%
FY2019Dec 31, 2019$143.09M+86.0%
FY2018Dec 31, 2018$76.93M+47.8%
FY2017Dec 31, 2017$52.03M+61.1%
FY2016Dec 31, 2016$32.30M-18.3%
FY2015Dec 31, 2015$39.53M+165.2%
FY2014Dec 31, 2014$14.91M+7.8%
FY2013Dec 31, 2013$13.83M+591.0%
FY2012Dec 31, 2012$2.00M-78.3%
FY2011Dec 31, 2011$9.24M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$225.39M-18.0%
Q1 FY2026Mar 31, 2026$243.18M-17.0%
Q4 FY2025Dec 31, 2025$269.00M-13.9%
Q3 FY2025Sep 30, 2025$265.41M+90.5%
Q2 FY2025Jun 30, 2025$274.86M+78.2%
Q1 FY2025Mar 31, 2025$292.94M+72.4%
Q4 FY2024Dec 31, 2024$312.40M+58.0%
Q3 FY2024Sep 30, 2024$139.33M+41.0%
Q2 FY2024Jun 30, 2024$154.24M+40.2%
Q1 FY2024Mar 31, 2024$169.87M+45.8%
Q4 FY2023Dec 31, 2023$197.67M+141.0%
Q3 FY2023Sep 30, 2023$98.84M-8.3%
Q2 FY2023Jun 30, 2023$110.00M-6.3%
Q1 FY2023Mar 31, 2023$116.49M-9.7%
Q4 FY2022Dec 31, 2022$82.02M+16.3%
Q3 FY2022Sep 30, 2022$107.76M-30.8%
Q2 FY2022Jun 30, 2022$117.34M-28.9%
Q1 FY2022Mar 31, 2022$128.94M-28.1%
Q4 FY2021Dec 31, 2021$70.54M-63.5%
Q3 FY2021Sep 30, 2021$155.80M-22.9%
Q2 FY2021Jun 30, 2021$165.11M+26.5%
Q1 FY2021Mar 31, 2021$179.27M+28.1%
Q4 FY2020Dec 31, 2020$193.43M+35.2%
Q3 FY2020Sep 30, 2020$202.03M+204.7%
Q2 FY2020Jun 30, 2020$130.47M+79.5%
Q1 FY2020Mar 31, 2020$139.93M+88.7%
Q4 FY2019Dec 31, 2019$143.09M+86.0%
Q3 FY2019Sep 30, 2019$66.31M-23.5%
Q2 FY2019Jun 30, 2019$72.70M-26.7%
Q1 FY2019Mar 31, 2019$74.17M+11.3%
Q4 FY2018Dec 31, 2018$76.93M+47.8%
Q3 FY2018Sep 30, 2018$86.73M+84.1%
Q2 FY2018Jun 30, 2018$99.13M+265.2%
Q1 FY2018Mar 31, 2018$66.61M+218.5%
Q4 FY2017Dec 31, 2017$52.03M+61.1%
Q3 FY2017Sep 30, 2017$47.11M-45.4%
Q2 FY2017Jun 30, 2017$27.15M–
Q1 FY2017Mar 31, 2017$20.92M–
Q4 FY2016Dec 31, 2016$32.30M–
Q3 FY2016Sep 30, 2016$86.23M–

More Neurogene figures

See a number that looks wrong?